4 completed, 2 terminated, 1 recruiting. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 4, Terminated 2, Recruiting 1 |
Follow Interferon-beta: new trials by email Literature Review of Interferon-beta trials Research Report on Interferon-beta
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial Colchicine, Interferon-Beta, Aspirin - Coronavirus, Severe Acute Respiratory Syndrome | Phase 3 | Completed | Population Health Research Institute | 6667 | 2020-04-21 | 2024-01-11 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon - Multiple Sclerosis | Phase 3 | Terminated | Genzyme, a Sanofi Company | 16 | 2017-10-23 | 2026-08-04 |
| Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) MP-424, RBV(24 weeks), IFN beta(24 weeks) - Chronic Hepatitis C(CHC) | Phase 3 | Completed | Tanabe Pharma Corporation | 74 | 2012-12-01 | 2026-01-06 |
| Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta Teriflunomide, Placebo (for teriflunomide), Interferon-beta (IFN-beta) - Multiple Sclerosis Relapse | Phase 3 | Terminated | Sanofi | 534 | 2011-01-01 | 2014-06-09 |
| Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis Interferon beta, Methotrexate - Uveitis, Intermediate, Macular Edema | Phase 3 | Completed | Heidelberg University | 19 | 2006-03-01 | 2012-12-03 |
| Optimizing IFN Beta - 1B Dose Interferon Beta 1 - Multiple Sclerosis | Phase 3 | Completed | University of Turin, Italy | 217 | 1999-09-01 | 2007-05-14 |
Multiple Sclerosis (4) · COVID-19 (1) · Coronavirus Infections (1) · Hepatitis C, Chronic (1) · Macular Edema (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Recurrence (1) · Severe Acute Respiratory Syndrome (1) · Uveitis (1) · Uveitis, Intermediate (1)
Genzyme, a Sanofi Company (1) · Heidelberg University (1) · Population Health Research Institute (1) · Sanofi (1) · Tanabe Pharma Corporation (1) · University Hospital, Montpellier (1) · University of Turin, Italy (1)
France (3) · Russia (3) · Brazil (2) · Canada (2) · Colombia (2) · Germany (2) · Italy (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Chile (1) · Denmark (1) · Ecuador (1)
Alessandra Protti, M.D. (1) · Andrea Spissu, M.D. (1) · Angelo Ghezzi, M.D. (1) · Antonio Carolei, M D (1) · Arturo Reggio, Prophessor (1) · Claudio Geda, M.D. (1) · Domenico Caputo, M.D. (1) · Elio Scarpini, M.D (1) · Emilie Belley-Cote, MD PhD (1) · Enrico Montanari, M.D. (1) · Federico Piccoli, Prophessor (1) · Francesco Teatini, M.D. (1) · Franco Perla, M.D. (1) · Friederike Mackensen, MD, FEBO (1)
PMID 19278300, PMID 28497489, PMID 34658014, PMID 36228639, PMID 36228641, PMID 37489818
2016 (1)